<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00338286</url>
  </required_header>
  <id_info>
    <org_study_id>CR005143</org_study_id>
    <secondary_id>EPOANE3010</secondary_id>
    <secondary_id>CR005143</secondary_id>
    <secondary_id>2005-001817-17</secondary_id>
    <nct_id>NCT00338286</nct_id>
  </id_info>
  <brief_title>A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy</brief_title>
  <official_title>A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the impact on tumor progression as evaluated by
      progression-free survival (PFS) of epoetin alfa plus standard supportive care as compared
      with standard supportive care alone (packed red blood cell (RBC) transfusions), for treating
      anemia according to label guidance in patients with metastatic breast cancer receiving
      standard chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anemia is a common complication of the treatment of metastatic breast cancer and is related
      to the effects of chemotherapy and to chronic disease itself. This is a randomized,
      open-label, multicenter, international study to further examine the safety of the study drug
      used with standard supportive care (i.e., packed RBC transfusions) compared to standard
      supportive care alone, when used to treat anemia associated with chemotherapy. This study
      will be done in subjects with metastatic breast cancer who are being or will be treated with
      first-line chemotherapy with standard dose schedules of taxane monotherapy, or a taxane plus
      trastuzumab, or an anthracycline plus either a taxane or cyclophosphamide. The study
      hypothesis is that epoetin alfa, when used as supportive anemia care, does not increase the
      risk of tumor progression or death. The study treatment will be compared to the control
      treatment by comparing progression-free survival, i.e., the number of months from the date a
      patient is randomized into the trial to the date of the first documented disease progression
      or death. In addition to their chemotherapy, half of the subjects will be assigned to receive
      study drug (epoetin alfa) and half of the subjects will be assigned to standard supportive
      care for anemia. Subjects treated with the study drug will receive standard supportive care
      (packed RBC transfusions) plus 40,000 IU epoetin alfa given subcutaneously once a week until
      4 weeks after the last cycle of chemotherapy or until disease progression, whichever comes
      first.The hypothesis is to test that epoetin alfa, when used as supportive anemia care, is
      non-inferior to control (standard supportive care alone), as measured by progression free
      survival (PFS). Patients treated with the study drug will receive standard supportive care
      (packed red blood cells (RBC) transfusions) plus 40,000 IU epoetin alfa given subcutaneously
      once a week until 4 weeks after the last cycle of chemotherapy or until disease progression,
      whichever comes first. Dose adjustments (dose escalation, dose reduction, dose interruption,
      and dose resumption) of epoetin alfa will be based on hemoglobin (Hb) and confirm to
      prescribing information.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2, 2006</start_date>
  <completion_date type="Actual">January 31, 2017</completion_date>
  <primary_completion_date type="Actual">July 7, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>From the date of randomization to the date of disease progression (PD) or death, whichever occurred first (up to 8.4 years)</time_frame>
    <description>Progression free survival was based in investigator-determined progressive disease (PD) and calculated from the date of randomization to the date of PD or the date of death, whichever occurred first. Participants who had not progressed and were still alive at the time of clinical cut off were censored at the last disease assessment prior to the clinical cutoff. For PD or death with a missing interval immediately preceding the event, progression-free survival (PFS) was censored at the last disease assessment prior to the missing interval. Participants who withdrew from the study (withdrawal of consent or lost to follow-up) without progression were censored at the time of the last disease assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From randomization up to death from any cause (up to 8.4 years)</time_frame>
    <description>Overall survival (OS) was defined as the interval between the date of randomization to the date of death from any cause. For participants who were lost to follow-up or withdrew before the final database lock, OS was censored at the last date the participants was known to be alive. For participants who were still alive and on study at the time of the final database lock, OS was censored at the date of final database lock.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Tumor Progression</measure>
    <time_frame>From date of randomization to the date of the first documented PD (up to 8.4 years)</time_frame>
    <description>The Time to tumor progression (TTP) was defined as the time from the date of starting treatment until the date of first documented evidence of progression of tumor. TTP was measured from the date of randomization to the date of the first documented PD (including death due to PD without prior PD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>every 8 weeks for 1 year and then every 12 weeks until PD or death, whichever occurred first (up to 8.4 years)</time_frame>
    <description>Overall response was RECIST criteria. Complete response (CR) is appearance of all target and non-target lesions. Partial response (PR):a) 30% decrease in sum of lactate dehydrogenase(LD) of target lesions from baseline OR b) complete disappearance of target lesions, with persistence of one or more non-target measurable lesion or one or more non-measurable, evaluable lesions. Progressive disease(PD):a) 20% increase in sum of LDs of target lesions, taking as reference smallest sum LD recorded since treatment started; OR b) appearance of one or more new lesions or a clear worsening of measurable non-target lesions or evaluable disease with stable measurable lesions. Stable disease (SD):a) sufficient shrinkage to qualify for PR;b) sufficient increase to qualify for PD. Non evaluable(NE) lesion: all other lesions, including small lesions (longest diameter &lt;20 millimeter (mm) with conventional techniques or &lt;10 mm with spiral CT scan) and truly non-measurable lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Suspected Thrombotic Vascular Events (TVEs)</measure>
    <time_frame>up to 8.4 years</time_frame>
    <description>Suspected TVEs were identified by investigators and relevant clinical information was collected.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2098</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>epoetin alfa + packed RBC transfusion 40 000 IU SC once a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>002</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard supportive care (packed RBC transfusion) Per doctor prescription</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard supportive care (packed RBC transfusion)</intervention_name>
    <description>Per doctor prescription</description>
    <arm_group_label>002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epoetin alfa + packed RBC transfusion</intervention_name>
    <description>40,000 IU SC once a week.</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed (e.g., slide of tissue) breast cancer

          -  HER2/NEU positive or negative

          -  Clinical evidence of metastasis (e.g., biopsy) with at least 1 measurable metastatic
             (M1) lesion prior to starting the current chemotherapy

          -  Received 1st and 2nd line chemotherapy

          -  Hemoglobin (Hb) &lt;= 11g/dL at the time of randomization

          -  planned to receive at least 2 more cycles of chemotherapy

          -  Life expectancy &gt; 6 months

          -  Eastern Cooperative Oncology Group score 0 or 1

          -  At least 18 years old using effective birth control or surgically sterile or
             postmenopausal for 1 year

        Exclusion Criteria:

          -  Active second cancer

          -  no recent history of clinically relevant thrombovascular event

          -  Current treatment with anticoagulants

          -  Brain metastasis or CNS involvement

          -  Anemia secondary to another cause

          -  Recent (within prior 1 months) use of an ESA

          -  Patient pregnant or breast feeding

          -  Progressive disease during adjuvant/neoadjuvant chemotherapy

          -  Rapidly progressive or life-threatening metastatic disease

          -  Concomitant endocrine therapy

          -  Patient in whom the only site of metastasis was local and was successfully treated
             surgically.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC C. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rockledge</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alexandria</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad Autonoma De Buenos Airess</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quilmes</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barretos</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Curitiba</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goiânia/Go</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ijuí</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jau</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Piracicaba</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ribeirão Preto/Sp</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santo Andre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>São José Do Rio Preto</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>São Paulol</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rousse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stara Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arica</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Temuco</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valdivia</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valparaiso</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Floridablanca-Santander</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monteria</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cuenca</city>
        <country>Ecuador</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guayaquil</city>
        <country>Ecuador</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portoviejo</city>
        <country>Ecuador</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quito</city>
        <country>Ecuador</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Batumi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tblisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Andra Pradesh</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangalore N/A</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bhopal</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cochin</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Karnad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kerala</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kolkata</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashik</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tamil Nadu Na</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tamil Nadu</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thiruvananthapuram</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uttar Pradesh</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vellore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bandung</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Semarang</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yogyakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bitola</city>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Skopje</city>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Georgetown</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kelantan</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nilai</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tanjung Bunga</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chihuahua</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guerrero</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leon</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merida</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morelia</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Puebla</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Luis Potosi</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sinaloa</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zapopan</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cebu</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Davao City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iloilo City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gliwice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katowice N/A</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olsztyn</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Onesti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suceava</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Balashikha</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Engels Saratov Region</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ivanovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leningrad Region</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lipetsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Magnitogorsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Obninsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orenburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perm</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pyatigorsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ryazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tyumen</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ufa</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Voronezh</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bloemfontein</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Klerksdorp</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Elizabeth N/A</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiayi</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hualien</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei 112</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tao-Yuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cherkassy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chernihiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chernivtsi</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dnepropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ivano-Francovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poltava</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sumy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uzhgorod</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vinnitsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vinnytsia</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaporozhye</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Ecuador</country>
    <country>Georgia</country>
    <country>Hong Kong</country>
    <country>India</country>
    <country>Indonesia</country>
    <country>Macedonia, The Former Yugoslav Republic of</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Former Serbia and Montenegro</country>
    <country>Kazakhstan</country>
    <country>Peru</country>
    <country>Serbia</country>
  </removed_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2006</study_first_submitted>
  <study_first_submitted_qc>June 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2006</study_first_posted>
  <results_first_submitted>December 22, 2015</results_first_submitted>
  <results_first_submitted_qc>February 23, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 24, 2016</results_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anemia</keyword>
  <keyword>metastatic breast cancer</keyword>
  <keyword>Hemoglobin</keyword>
  <keyword>progression-free survival (PFS)</keyword>
  <keyword>erythropoiesis-stimulating agents (ESA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants in safety data were grouped as treatment actually received (3 were assigned to SOC but received epoetin alfa; 2 were assigned to EPO, but received SOC) so, 1 more to EPO (1051) 1 less in SOC (1045) actually received treatment. Efficacy, safety were analyzed by 1050 (EPO), 1048 (SOC), 1051 (EPO), 1045 (SOC) respectively.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard Supportive Care (SOC)</title>
          <description>Participants received standard supportive care as packed red blood cells (RBC) transfusion as per Investigator's discretion</description>
        </group>
        <group group_id="P2">
          <title>Epoetin Alfa</title>
          <description>Participants received SOC plus epoetin alfa 40,000 international units (IU) subcutaneously (SC) once a week.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1048"/>
                <participants group_id="P2" count="1050"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="815"/>
                <participants group_id="P2" count="837"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="233"/>
                <participants group_id="P2" count="213"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="93"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The intent to treat (ITT) population included all participants who were randomized in either Standard of Care (SOC) or Epoetin alfa group.</population>
      <group_list>
        <group group_id="B1">
          <title>Standard Supportive Care (SOC)</title>
          <description>Participants received standard supportive care as packed red blood cells (RBC) transfusion as per Investigator's discretion</description>
        </group>
        <group group_id="B2">
          <title>Epoetin Alfa</title>
          <description>Participants received SOC plus epoetin alfa 40,000 international units (IU) subcutaneously (SC) once a week.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1048"/>
            <count group_id="B2" value="1050"/>
            <count group_id="B3" value="2098"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.8" spread="10.54"/>
                    <measurement group_id="B2" value="51.9" spread="10.49"/>
                    <measurement group_id="B3" value="51.9" spread="10.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1048"/>
                    <measurement group_id="B2" value="1050"/>
                    <measurement group_id="B3" value="2098"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>ARGENTINA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRAZIL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BULGARIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CHILE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COLOMBIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECUADOR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GEORGIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="241"/>
                    <measurement group_id="B2" value="200"/>
                    <measurement group_id="B3" value="441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HONG KONG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INDIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="211"/>
                    <measurement group_id="B2" value="237"/>
                    <measurement group_id="B3" value="448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INDONESIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MACEDONIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MALAYSIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MEXICO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PHILIPPINES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ROMANIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RUSSIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TAIWAN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UKRAINE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="328"/>
                    <measurement group_id="B2" value="318"/>
                    <measurement group_id="B3" value="646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UNITED STATES OF AMERICA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival</title>
        <description>Progression free survival was based in investigator-determined progressive disease (PD) and calculated from the date of randomization to the date of PD or the date of death, whichever occurred first. Participants who had not progressed and were still alive at the time of clinical cut off were censored at the last disease assessment prior to the clinical cutoff. For PD or death with a missing interval immediately preceding the event, progression-free survival (PFS) was censored at the last disease assessment prior to the missing interval. Participants who withdrew from the study (withdrawal of consent or lost to follow-up) without progression were censored at the time of the last disease assessment.</description>
        <time_frame>From the date of randomization to the date of disease progression (PD) or death, whichever occurred first (up to 8.4 years)</time_frame>
        <population>The intent to treat (ITT) population included all participants who were randomized in either Standard of Care (SOC) or Epoetin alfa group.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care (SOC)</title>
            <description>Participants received standard supportive care as packed red blood cells (RBC) transfusion as per Investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants received SOC plus epoetin alfa 40,000 international units (IU) subcutaneously (SC) once a week.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Progression free survival was based in investigator-determined progressive disease (PD) and calculated from the date of randomization to the date of PD or the date of death, whichever occurred first. Participants who had not progressed and were still alive at the time of clinical cut off were censored at the last disease assessment prior to the clinical cutoff. For PD or death with a missing interval immediately preceding the event, progression-free survival (PFS) was censored at the last disease assessment prior to the missing interval. Participants who withdrew from the study (withdrawal of consent or lost to follow-up) without progression were censored at the time of the last disease assessment.</description>
          <population>The intent to treat (ITT) population included all participants who were randomized in either Standard of Care (SOC) or Epoetin alfa group.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1048"/>
                <count group_id="O2" value="1050"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" lower_limit="7.1" upper_limit="7.6"/>
                    <measurement group_id="O2" value="7.4" lower_limit="6.9" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival (OS) was defined as the interval between the date of randomization to the date of death from any cause. For participants who were lost to follow-up or withdrew before the final database lock, OS was censored at the last date the participants was known to be alive. For participants who were still alive and on study at the time of the final database lock, OS was censored at the date of final database lock.</description>
        <time_frame>From randomization up to death from any cause (up to 8.4 years)</time_frame>
        <population>The intent to treat (ITT) population included all participants who were randomized in either Standard of Care (SOC) or Epoetin alfa group.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care (SOC)</title>
            <description>Participants received standard supportive care as packed red blood cells (RBC) transfusion as per Investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants received SOC plus epoetin alfa 40,000 international units (IU) subcutaneously (SC) once a week.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival (OS) was defined as the interval between the date of randomization to the date of death from any cause. For participants who were lost to follow-up or withdrew before the final database lock, OS was censored at the last date the participants was known to be alive. For participants who were still alive and on study at the time of the final database lock, OS was censored at the date of final database lock.</description>
          <population>The intent to treat (ITT) population included all participants who were randomized in either Standard of Care (SOC) or Epoetin alfa group.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1048"/>
                <count group_id="O2" value="1050"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" lower_limit="16.6" upper_limit="19.6"/>
                    <measurement group_id="O2" value="17.8" lower_limit="16.6" upper_limit="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Tumor Progression</title>
        <description>The Time to tumor progression (TTP) was defined as the time from the date of starting treatment until the date of first documented evidence of progression of tumor. TTP was measured from the date of randomization to the date of the first documented PD (including death due to PD without prior PD).</description>
        <time_frame>From date of randomization to the date of the first documented PD (up to 8.4 years)</time_frame>
        <population>The intent to treat (ITT) population included all participants who were randomized in either Standard of Care (SOC) or Epoetin alfa group.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care (SOC)</title>
            <description>Participants received standard supportive care as packed red blood cells (RBC) transfusion as per Investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants received SOC plus epoetin alfa 40,000 international units (IU) subcutaneously (SC) once a week.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Tumor Progression</title>
          <description>The Time to tumor progression (TTP) was defined as the time from the date of starting treatment until the date of first documented evidence of progression of tumor. TTP was measured from the date of randomization to the date of the first documented PD (including death due to PD without prior PD).</description>
          <population>The intent to treat (ITT) population included all participants who were randomized in either Standard of Care (SOC) or Epoetin alfa group.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1048"/>
                <count group_id="O2" value="1050"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="7.4" upper_limit="8.0"/>
                    <measurement group_id="O2" value="7.5" lower_limit="7.4" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate (ORR)</title>
        <description>Overall response was RECIST criteria. Complete response (CR) is appearance of all target and non-target lesions. Partial response (PR):a) 30% decrease in sum of lactate dehydrogenase(LD) of target lesions from baseline OR b) complete disappearance of target lesions, with persistence of one or more non-target measurable lesion or one or more non-measurable, evaluable lesions. Progressive disease(PD):a) 20% increase in sum of LDs of target lesions, taking as reference smallest sum LD recorded since treatment started; OR b) appearance of one or more new lesions or a clear worsening of measurable non-target lesions or evaluable disease with stable measurable lesions. Stable disease (SD):a) sufficient shrinkage to qualify for PR;b) sufficient increase to qualify for PD. Non evaluable(NE) lesion: all other lesions, including small lesions (longest diameter &lt;20 millimeter (mm) with conventional techniques or &lt;10 mm with spiral CT scan) and truly non-measurable lesions.</description>
        <time_frame>every 8 weeks for 1 year and then every 12 weeks until PD or death, whichever occurred first (up to 8.4 years)</time_frame>
        <population>The intent to treat (ITT) population included all participants who were randomized in either Standard of Care (SOC) or Epoetin alfa group.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care (SOC)</title>
            <description>Participants received standard supportive care as packed red blood cells (RBC) transfusion as per Investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants received SOC plus epoetin alfa 40,000 international units (IU) subcutaneously (SC) once a week.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR)</title>
          <description>Overall response was RECIST criteria. Complete response (CR) is appearance of all target and non-target lesions. Partial response (PR):a) 30% decrease in sum of lactate dehydrogenase(LD) of target lesions from baseline OR b) complete disappearance of target lesions, with persistence of one or more non-target measurable lesion or one or more non-measurable, evaluable lesions. Progressive disease(PD):a) 20% increase in sum of LDs of target lesions, taking as reference smallest sum LD recorded since treatment started; OR b) appearance of one or more new lesions or a clear worsening of measurable non-target lesions or evaluable disease with stable measurable lesions. Stable disease (SD):a) sufficient shrinkage to qualify for PR;b) sufficient increase to qualify for PD. Non evaluable(NE) lesion: all other lesions, including small lesions (longest diameter &lt;20 millimeter (mm) with conventional techniques or &lt;10 mm with spiral CT scan) and truly non-measurable lesions.</description>
          <population>The intent to treat (ITT) population included all participants who were randomized in either Standard of Care (SOC) or Epoetin alfa group.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1048"/>
                <count group_id="O2" value="1050"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive disease (PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not evaluable (NE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not available (NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Suspected Thrombotic Vascular Events (TVEs)</title>
        <description>Suspected TVEs were identified by investigators and relevant clinical information was collected.</description>
        <time_frame>up to 8.4 years</time_frame>
        <population>The intent to treat (ITT) population included all participants who were randomized in either Standard of Care (SOC) or Epoetin alfa group.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care (SOC)</title>
            <description>Participants received standard supportive care as packed red blood cells (RBC) transfusion as per Investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants received SOC plus epoetin alfa 40,000 international units (IU) subcutaneously (SC) once a week.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Suspected Thrombotic Vascular Events (TVEs)</title>
          <description>Suspected TVEs were identified by investigators and relevant clinical information was collected.</description>
          <population>The intent to treat (ITT) population included all participants who were randomized in either Standard of Care (SOC) or Epoetin alfa group.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1048"/>
                <count group_id="O2" value="1050"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.72"/>
                    <measurement group_id="O2" value="4.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From randomization up to 8.4 years</time_frame>
      <desc>The Safety analysis set included included all randomized participants for whom safety assessment data were available. Participants in the safety population were grouped according to the treatment actually received.</desc>
      <group_list>
        <group group_id="E1">
          <title>Standard Supportive Care (SOC)</title>
          <description>Participants received standard supportive care as packed red blood cells (RBC) transfusion as per Investigator's discretion</description>
        </group>
        <group group_id="E2">
          <title>Epoetin Alfa</title>
          <description>Participants received SOC plus epoetin alfa 40,000 international units (IU) subcutaneously (SC) once a week.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 19.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="229" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="251" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Bone Marrow Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Neutrophilia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis Coronary Artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Cardiac Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Cardiac Tamponade</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Cardio-Respiratory Arrest</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Cardiovascular Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Cyanosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Left Ventricular Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Left Ventricular Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Sinus Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Amaurosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Retinal Artery Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Jejunal Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Lower Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Mouth Ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Oral Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Pancreatitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Peptic Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Disease Progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Facial Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Generalised Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Mucosal Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Multiple Organ Dysfunction Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Peripheral Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Hepatic Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Cholecystitis Chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Hepatic Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Hepatic Lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Hepatitis Toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Hepatorenal Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Jaundice Hepatocellular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Biliary Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Breast Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Breast Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary Aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Candida Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Device Related Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Fungal Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Groin Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Hepatitis Viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Infectious Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Injection Site Abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Neutropenic Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Neutropenic Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Plasmodium Falciparum Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Pulmonary Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Tuberculosis Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Femoral Neck Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Post Procedural Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Radius Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Rib Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Biopsy Liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus Inadequate Control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Electrolyte Imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Failure to Thrive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Pain in Jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Pathological Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Soft Tissue Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Cervix Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Lymphangiosis Carcinomatosa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Malignant Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Metastases to Central Nervous System</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Metastases to Liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Metastases to Meninges</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Metastases to the Respiratory System</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Oncologic Complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Rectal Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Tumour Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Uterine Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered State of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Brain Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Central Nervous System Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Cerebral Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Depressed Level of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Diabetic Hyperglycaemic Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Haemorrhage Intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Cerebral Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Hepatic Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Hypoxic-Ischaemic Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Iiird Nerve Paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Incoherent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Intracranial Pressure Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Loss of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Neuropathy Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Peripheral Motor Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Peripheral Sensorimotor Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Peripheral Sensory Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Vertebral Artery Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device Breakage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Behaviour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Depressed Mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Mental Status Changes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Ovarian Cyst Torsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Pelvic Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Uterine Polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Distress Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Alveolitis Allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Orthopnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Pneumonia Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Pulmonary Artery Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Pulmonary Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Pulmonary Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Pulmonary Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Respiratory Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Respiratory Arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Restrictive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Dermatitis Exfoliative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Intertrigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Palmar-Plantar Erythrodysaesthesia Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Skin Lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Stevens-Johnson Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Hypovolaemic Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Superior Vena Cava Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Vena Cava Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Venous Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 19.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="883" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="898" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="153" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="279" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="270" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="550" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="530" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="189" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="180" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="232" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="257" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="139" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="215" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="201" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="190" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="182" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Neuropathy Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Peripheral Sensory Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="1051"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="326" subjects_at_risk="1045"/>
                <counts group_id="E2" subjects_affected="314" subjects_at_risk="1051"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Clinical Research</name_or_title>
      <organization>Janssen Research and Development</organization>
      <email>ClinicalTrialDisclosure@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

